COMMUNIQUÉS West-GlobeNewswire

Ossur Hf : Transactions in relation to share buyback program
21/01/2019
Announcement no. 04/2019 21 January 2019 Transactions in relation to share buyback program On 9 October 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2018. The purpose of the share [...]
Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10)
21/01/2019
CAMBRIDGE, Mass., Jan. 21, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the journal Nature Medicine published the comprehensive, pre-clinical data [...]
SciCann Therapeutics launch liver disease research program in Tel Aviv University
21/01/2019
TORONTO and TEL AVIV, Israel, Jan. 21, 2019 (GLOBE NEWSWIRE) -- SciCann Therapeutics is pleased to announce that it has launched a novel sponsored research program in Tel Aviv University, focused on the field of liver [...]
Allocation of Share Options
21/01/2019
NASDAQ Copenhagen Report on transactions of executives and related parties in Coloplast shares and related securities. According to the Market Abuse Regulation art. 19 Coloplast is obliged to report on the transactions [...]
Physeon Positive Clinical Trial Results for its Veinplicity® Device Published in The Journal of Vascular Access
21/01/2019
Results Confirmed that Veinplicity Dilatory Effect is 38% Greater than Commonly Used Heat Packs SCHAFFHAUSEN, Switzerland, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading [...]
Sandoz Canada reçoit l’approbation de Santé Canada pour l’utilisation d’Erelzi® (étanercept) dans le traitement de l’arthrite psoriasique chez les patients adultes
21/01/2019
Erelzi est le seul biosimilaire d’étanercept indiqué pour réduire les signes et les symptômes de l’arthrite psoriasique chez les patients adultes. Jusqu’à 90 000 Canadiens et Canadiennes souffrent ou pourraient souffrir [...]
Novo Nordisk A/S - Share repurchase programme
21/01/2019
Bagsværd, Denmark, 21 January 2019 - On 5 November 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Solo Growth Announces Update to Corporate Presentation
21/01/2019
CALGARY, Alberta, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Solo Growth Corp.™ (the “ Company ” or “ Solo Growth ”) (TSXV: SOLO) is pleased to announce that we have updated our corporate presentation, which is now posted on our [...]
Nash Pharmaceuticals Announces 84% Reduction of Fibrosis by Additional Lead Compound In Second Pre-Clinical Study For Non-Alcoholic Fatty Liver Disease
21/01/2019
Compound Showed Marked Improvement Over Cenicriviroc VANCOUVER, British Columbia, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH ) (CNSX: [...]
FocusCura subsidiary Luscii will continue as independent company with partner OMRON Healthcare to accelerate their international expansion
21/01/2019
Joining forces supports hospitals in moving care towards the home AMSTERDAM, The Netherlands, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Luscii, the e-health application for remote monitoring developed by FocusCura, is set to [...]
Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology
21/01/2019
Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) [...]
Oasmia announces that the extraordinary general meeting 25 January 2019 is cancelled
21/01/2019
Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) hereby announces that the board of directors of the Company has resolved to cancel the extraordinary general meeting which was to be held 25 January 2019. [...]
Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE™ Exhibits Durability Following Second Dose
20/01/2019
ALPHARETTA, Ga., Jan. 20, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye [...]
Media Advisory: Top Smoking Cessation Experts Meet in Ottawa
19/01/2019
OTTAWA, Jan. 19, 2019 (GLOBE NEWSWIRE) -- National and international smoking cessation authorities are gathering in Ottawa today to attend the second and final day of the 11 th Annual Ottawa Conference: State of the Art [...]
Avis aux médias : Les plus grands experts de l’abandon du tabac se rassemblent à Ottawa
19/01/2019
OTTAWA, 19 janv. 2019 (GLOBE NEWSWIRE) -- Des experts du Canada et du monde entier se rassemblent à Ottawa aujourd’hui pour la deuxième et dernière journée de la 11 e Conférence annuelle d’Ottawa : Approches cliniques [...]
Les animaux de Taconic Biosciences effectuent la dernière mission à la Station spatiale internationale
18/01/2019
RENSSELAER, New York, 18 janv. 2019 (GLOBE NEWSWIRE) -- Taconic Biosciences, chef de file mondial dans la fourniture de modèles de rongeurs génétiquement modifiés, annonce l'achèvement d'une récente mission à la Station [...]
iKang Announces Completion of Going Private Transaction
18/01/2019
BEIJING, Jan. 18, 2019 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq: KANG), a major provider in China’s fast growing private preventive healthcare services market, today announced [...]
MPX Receives Final Court Approval for Arrangement with iAnthus
18/01/2019
NEW YORK and TORONTO, Jan. 18, 2019 (GLOBE NEWSWIRE) -- iAnthus Capital Holdings, Inc. (“ iAnthus ” or the “ Company ”), (CSE: IAN , OTCQB: ITHUF) and MPX Bioceutical Corporation (“ MPX ”) (CSE: MPX; OTC: MPXEF) are [...]
Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering Priced At-the-Market
18/01/2019
HOUSTON, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio [...]

Pages